Increased incidence of co-infection in critically ill patients with influenza

Intensive Care Medicine

Volumn 43, Issue 1, 2017, Pages 48-58

  Martin Loeches, Ignacio ^a,b   J Schultz, Marcus ^c   Vincent, Jean Louis ^d   Alvarez Lerma, Francisco ^e   Bos, Lieuwe D ^c   Solé Violán, Jordi ^f   Torres, Antoni ^g   Rodriguez, Alejandro ^b,h  

^a ST JAMES S HOSPITAL   (Ireland)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ERASME HOSPITAL   (Belgium)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

Co infection; Influenza; Intensive care; Outcome; Risk factors

Indexed keywords

ACINETOBACTER INFECTION; ADULT; ARTICLE; ASPERGILLOSIS; BACTEROIDES INFECTION; CHLAMYDIAL PNEUMONIA; CLINICAL OUTCOME; COMMUNITY ACQUIRED INFECTION; CRITICALLY ILL PATIENT; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL MORTALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNE DEFICIENCY; INFECTION RISK; INFLUENZA; INTENSIVE CARE UNIT; KLEBSIELLA INFECTION; KLEBSIELLA OXYTOCA; LEGIONNAIRE DISEASE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MIXED INFECTION; MORGANELLA MORGANII; MORTALITY RISK; MYCOPLASMA PNEUMONIA; NOCARDIOSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; SERRATIA INFECTION; SHEWANELLA; SPAIN; STAPHYLOCOCCUS HOMINIS; STAPHYLOCOCCUS INFECTION; STENOTROPHOMONAS MALTOPHILIA; TUBERCULOSIS; AGED; CLINICAL TRIAL; CRITICAL ILLNESS; INCIDENCE; MULTICENTER STUDY; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COINFECTION; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL ILLNESS; FEMALE; HUMANS; INCIDENCE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 84990889967     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-016-4578-y     Document Type: Article

References (28)

1. Napolitano LM, Angus DC, Uyeki TM (2014) Critically ill patients with influenza A(H1N1)pdm09 virus infection in 2014. JAMA 311(13):1289–1290. doi:10.1001/jama.2014.2116
2. Rodríguez A, Díaz E, Martín-Loeches I et al (2011) Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 66:1140–1149. doi:10.1093/jac/dkq511
3. Martin-Loeches I, Bermejo-Martin JF, Valles J et al (2013) Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia. Intensive Care Med 39:693–702. doi:10.1007/s00134-013-2829-8
4. Chertow DS (2012) Contribution of bacterial coinfection to severe influenza infection. Crit Care Med 40:1664–1665. doi:10.1097/CCM.0b013e3182451fd8
5. Sheng Z-M, Chertow DS, Ambroggio X et al (2011) Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci USA 108:16416–16421. doi:10.1073/pnas.1111179108
6. Giles C, Shuttleworth EM (1957) Postmortem findings in 46 influenza deaths. Lancet (London, England) 273:1224–5
7. Martin-Loeches I, Valles J (2012) Overtreating or underdiagnosing invasive pulmonary aspergillosis (IPA) in critically ill H1N1 patients: who is right? Intensive Care Med 38:1733–1735. doi:10.1007/s00134-012-2677-y
8. van der Sluijs KF, van der Poll T, Lutter R et al (2010) Bench-to-bedside review: bacterial pneumonia with influenza—pathogenesis and clinical implications. Crit Care 14:219. doi:10.1186/cc8893
9. http://vgripe.isciii.es/gripe/inicio.do. Accessed 20 June 2016
10. Alfageme I, Aspa J, Bello S et al (2005) Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 41:272–289
11. Mandell LA, Wunderink G, Anzueto A et al (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72. doi:10.1086/511159
12. Schoenfeld DA, Bernard GR, Network ARDS (2002) Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 30:1772–1777
13. Martín-Loeches I, Sanchez-Corral A, Diaz E et al (2011) Community-acquired respiratory coinfection in critically ill patients with pandemic 2009 influenza A(H1N1) virus. Chest 139:555–562. doi:10.1378/chest.10-1396
14. Rice TW, Rubinson L, Uyeki TM et al (2012) Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 40:1487–1498. doi:10.1097/CCM.0b013e3182416f23
15. Kakeya H, Seki M, Izumikawa K et al (2014) Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study. PLoS ONE 9:e91293. doi:10.1371/journal.pone.0091293
16. Martin-Loeches I, Lisboa T, Rhodes A, et al. (2010) Use of corticosteroid therapy in patients affected by severe pandemic (H1N1) V influenza A infection. Intensive Care Med. pp S319–S319
17. Pereira JM, Moreno RP, Matos R et al (2012) Severity assessment tools in ICU patients with 2009 influenza A (H1N1) pneumonia. Clin Microbiol Infect 18:1040–1048. doi:10.1111/j.1469-0691.2011.03736.x
18. Parnell GP, McLean AS, Booth DR et al (2012) A distinct influenza infection signature in the blood transcriptome of patients who presented with severe community acquired pneumonia. Crit Care 16:R157. doi:10.1186/cc11477
19. Martin-Loeches I, Papiol E, Rodríguez A et al (2011) Acute kidney injury in critical ill patients affected by influenza A (H1N1) virus infection. Crit Care 15:R66. doi:10.1186/cc10046
20. Muscedere J, Ofner M, Kumar A et al (2013) The occurrence and impact of bacterial organisms complicating critical care illness associated with 2009 influenza A(H1N1) infection. Chest 144:39–47. doi:10.1378/chest.12-1861
21. Klein EY, Monteforte B, Gupta A et al (2016) The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influ Other Respi Viruses 10:394–403. doi:10.1111/irv.12398
22. Martin-Loeches I, Díaz E, Vidaur L et al (2011) Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. Crit Care 15:R286. doi:10.1186/cc10573
23. Martin-Loeches I, Lisboa T, Rodriguez A et al (2010) Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36:612–620
24. Muthuri SG, Venkatesan S, Myles PR et al (2014) Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2:395–404. doi:10.1016/S2213-2600(14)70041-4
25. Vallés J, Martin-Loeches I, Torres A et al (2014) Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. Intensive Care Med. doi:10.1007/s00134-014-3239-2
26. (2014) NICE. National Institute for Health and Care Excellence. Pneumonia (including community acquired pneumonia). http://www.nice.org.uk/guidance/cg191. Accessed 20 June 2016
27. Estella A (2010) Bronchoalveolar lavage for pandemic influenza A (H1N1)v pneumonia in critically ill patients. Intensive Care Med 36:1976–1977. doi:10.1007/s00134-010-2009-z
28. Fowlkes A, Steffens A, Temte J et al (2015) Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-13. Lancet Respir Med 3:709–718. doi:10.1016/S2213-2600(15)00278-7